Imricor (IMR) March Quarterly Report: Progressing Towards FDA Registration Strategy

2021-04-29 05:29:42 (AET) by Ring Zhang

Imricor Medical Systems (ASX: IMR) released its quarterly report for the three months ended 31 March 2021, providing investors with business updates associated with its leading MRI-guided cardiac ablation products, as well as financial and operational performance.

Imricor Medical Systems (ASX: IMR), an ASX-listed medical devices producer, released its quarterly report for the three months ended 31 March 2021, providing investors with business update associated with its leading MRI-guided cardiac ablation products, and financial and operational performance.

The company reported cash receipts from customer of US$0.234 million and held US$20.68 million at period end. Estimated quarters of funding available at the same spending level would be 5.1 quarters.

As most countries in Europe reinitiated COVID-19 measures in response to the new wave of outbreak, Imricor confirmed that it has slowed down its new iCMR Lab roll-out plan. Moreover, the company’s contracted partners, including Leipzig Heart Centre and Maastricht University Medical Centre, have both temporarily halted procedures again due to the latest lockdown measures undertaken in Germany and Netherlands.

The company expects the measures in Germany will remain until June this year, while the Netherlands will start to ease restrictions next week. Notwithstanding these restrictions, Imricor is working closely with contracted sites to progress installation, training, and the commencement of operations as soon as allowed.
Currently, Imricor has 9 contracted sites and revealed that the signing of new agreements will recommence in the second quarter and accelerate in the second half of FY21.

In addition, the company is advancing the implementation of FDA strategy for its MRI-guided cardiac ablation products. Following the third pre-submission meeting with the US FDA, the company is confident in the study design of the clinical program, which is scheduled to commence in July this year.

In Australia, Imricor has appointed a local specialist Regional Health Care Group (RHCG) to facilitate TGA approval. As part of the service agreement, RHCG will be the exclusive distributor of Imricor’s consumable products in Australia and New Zealand and a non-exclusive distributor of Imricor’s capital equipment.

Expanding indications and opportunities beyond cardiac ablation has been a priority of the company. Imricor is currently researching and developing steerable sheaths and transseptal needles which, in the future, will enable access to the left side of the heart via the intra-atrial septum, for some more complex procedures. It is anticipated that these products will be ready for clinical trial during 2021.

In the meantime, the development program of Imricor’s diagnostic catheter is progressing well, aiming for commercial releases in late 2021 or early 2022.




版权所有,转载需注明出处:61 澳洲财经资讯


61 澳洲财经资讯邮件订阅服务,每日为您推荐最新澳洲财经资讯


金/锂多元化勘探商Hawkstone Mining (HWK) 已在美国OTC市场交易

金/锂多元化勘探商Hawkstone Mining Ltd(ASX:HWK)宣布开始在美国OTCQB市场以OTCQB:HWKMF代码进行交易,此次二次上市得益于北美投资商的对公司的浓厚兴趣,也是公司决定提高投资者对其美国亚利桑那州100%拥有Big Sandy锂项目的认识的战略计划部分。

Matsa Resources (MAT) 已开始Lake Carey项目6个优先靶区的反循环钻探

金矿勘探商Matsa Resources Limited(ASX:MAT)宣布已开始在Devon矿坑开始6个高优先级靶区区域的反循环钻探。这些靶区的高优先级依据来自Matsa 2020年进行的亚音频电磁(SAM)调查、最近的土壤和岩石碎屑样本结果、最近的地质制图以及Devon的新地质和资源模型。


维州金矿勘探公司Dart Mining NL(ASX:DTM)宣布,已在其位于维州东北部全资拥有的Granite Flat项目中开始后续钻探计划,这基于其2020年钻探活动中交汇的铜金矿化。 Dart将使用公司最近购置的Atlas Copco Diamec 262金刚石钻机来进行此次钻探活动,这将为未来的钻探计划节省大量成本并提高灵活性。


Imricor signed distribution agreement to facilitate sales in Australia and NZ

Imricor Medical Systems (ASX: IMR) signed a Distribution Agreement with Sydney-based medical device distributor Regional Health Care Group Pty Ltd (RGCH). Pursuant to the agreement, RHCG will be the exclusive distributor of Imicor's consumable products in Australia and New Zealand, and a non-exclusive distributor of Imicor's capital equipment.

脱水简报- Imricor Medical Systems个股分析

Imricor Medical Systems,Inc. (ASX:IMR)是一家位于美国的医疗设备公司。该公司专注于设计,制造和销售与磁共振成像(MRI)兼容的产品,这些产品可用于治疗心律失常的心脏导管消融手术。


可视化心脏消融设备公司Imricor Medical Systems,Inc.( ASX:IMR)宣布,已与德国柏林布赫Helios综合性医院(Helios Hospital Berlin-Buch)签署协议,成为第十个建立iCMR(介入性心脏磁共振成像)实验室的临床站点,将采用Imricor的产品在由MRI引导的环境下进行可视化的心脏消融手术。